Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX.

Mol Cancer Ther. 2018 Feb;17(2):474-483. doi: 10.1158/1535-7163.MCT-16-0818. Epub 2017 Dec 28.

PMID:
29284644
2.

Abasic and oxidized ribonucleotides embedded in DNA are processed by human APE1 and not by RNase H2.

Malfatti MC, Balachander S, Antoniali G, Koh KD, Saint-Pierre C, Gasparutto D, Chon H, Crouch RJ, Storici F, Tell G.

Nucleic Acids Res. 2017 Nov 2;45(19):11193-11212. doi: 10.1093/nar/gkx723.

3.

The biodistribution and pharmacokinetics of the oxime acetylcholinesterase reactivator RS194B in guinea pigs.

Malfatti MA, Enright HA, Be NA, Kuhn EA, Hok S, McNerney MW, Lao V, Nguyen TH, Lightstone FC, Carpenter TS, Bennion BJ, Valdez CA.

Chem Biol Interact. 2017 Nov 1;277:159-167. doi: 10.1016/j.cbi.2017.09.016. Epub 2017 Sep 21.

4.

Maternal exposure to an environmentally relevant dose of triclocarban results in perinatal exposure and potential alterations in offspring development in the mouse model.

Enright HA, Falso MJS, Malfatti MA, Lao V, Kuhn EA, Hum N, Shi Y, Sales AP, Haack KW, Kulp KS, Buchholz BA, Loots GG, Bench G, Turteltaub KW.

PLoS One. 2017 Aug 9;12(8):e0181996. doi: 10.1371/journal.pone.0181996. eCollection 2017.

5.

Unveiling the non-repair face of the Base Excision Repair pathway in RNA processing: A missing link between DNA repair and gene expression?

Antoniali G, Malfatti MC, Tell G.

DNA Repair (Amst). 2017 Aug;56:65-74. doi: 10.1016/j.dnarep.2017.06.008. Epub 2017 Jun 9. Review.

PMID:
28629776
6.

Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data.

Bennion BJ, Be NA, McNerney MW, Lao V, Carlson EM, Valdez CA, Malfatti MA, Enright HA, Nguyen TH, Lightstone FC, Carpenter TS.

J Phys Chem B. 2017 May 25;121(20):5228-5237. doi: 10.1021/acs.jpcb.7b02914. Epub 2017 May 12.

7.

A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.

Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT.

Int J Cancer. 2017 Aug 1;141(3):604-613. doi: 10.1002/ijc.30747. Epub 2017 May 15.

PMID:
28437852
8.

Mass Spectrometric Characterization of an Acid-Labile Adduct Formed with 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Albumin in Humans.

Wang Y, Villalta PW, Peng L, Dingley K, Malfatti MA, Turteltaub KW, Turesky RJ.

Chem Res Toxicol. 2017 Feb 20;30(2):705-714. doi: 10.1021/acs.chemrestox.6b00426. Epub 2017 Jan 18.

9.

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT.

Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.

10.

Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

Enright HA, Malfatti MA, Zimmermann M, Ognibene T, Henderson P, Turteltaub KW.

Chem Res Toxicol. 2016 Dec 19;29(12):1976-1986. Epub 2016 Oct 11. Review.

11.

Diagnostic Microdosing Approach to Study Gemcitabine Resistance.

Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT.

Chem Res Toxicol. 2016 Nov 21;29(11):1843-1848. Epub 2016 Oct 10.

12.

Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans.

Malfatti MA, Kuhn EA, Turteltaub KW, Vickers SM, Jensen EH, Strayer L, Anderson KE.

Chem Res Toxicol. 2016 Mar 21;29(3):352-8. doi: 10.1021/acs.chemrestox.5b00495. Epub 2016 Mar 8.

13.

Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.

Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT.

PLoS One. 2016 Jan 22;11(1):e0146256. doi: 10.1371/journal.pone.0146256. eCollection 2016.

14.

Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity.

Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson PT, Pan CX.

Chem Res Toxicol. 2015 Dec 21;28(12):2250-2. doi: 10.1021/acs.chemrestox.5b00422. Epub 2015 Nov 11.

15.

Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.

Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, Britton RG, Horner-Glister E, Greaves P, Jawad D, James M, Howells L, Ognibene T, Malfatti M, Goldring C, Kitteringham N, Walsh J, Viskaduraki M, West K, Miller A, Hemingway D, Steward WP, Gescher AJ, Brown K.

Sci Transl Med. 2015 Jul 29;7(298):298ra117. doi: 10.1126/scitranslmed.aaa7619.

16.

Inhibitors of the apurinic/apyrimidinic endonuclease 1 (APE1)/nucleophosmin (NPM1) interaction that display anti-tumor properties.

Poletto M, Malfatti MC, Dorjsuren D, Scognamiglio PL, Marasco D, Vascotto C, Jadhav A, Maloney DJ, Wilson DM 3rd, Simeonov A, Tell G.

Mol Carcinog. 2016 May;55(5):688-704. doi: 10.1002/mc.22313. Epub 2015 Apr 11.

17.

New surface radiolabeling schemes of super paramagnetic iron oxide nanoparticles (SPIONs) for biodistribution studies.

Nallathamby PD, Mortensen NP, Palko HA, Malfatti M, Smith C, Sonnett J, Doktycz MJ, Gu B, Roeder RK, Wang W, Retterer ST.

Nanoscale. 2015 Apr 21;7(15):6545-55. doi: 10.1039/c4nr06441k.

18.

Human in Vivo Pharmacokinetics of [(14)C]Dibenzo[def,p]chrysene by Accelerator Mass Spectrometry Following Oral Microdosing.

Madeen E, Corley RA, Crowell S, Turteltaub K, Ognibene T, Malfatti M, McQuistan TJ, Garrard M, Sudakin D, Williams DE.

Chem Res Toxicol. 2015 Jan 20;28(1):126-34. doi: 10.1021/tx5003996. Epub 2014 Dec 10.

19.

Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats.

Malfatti MA, Lao V, Ramos CL, Ong VS, Turteltaub KW.

Antimicrob Agents Chemother. 2014 Nov;58(11):6477-83. doi: 10.1128/AAC.03300-14. Epub 2014 Aug 18.

20.

DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry.

Dingley KH, Ubick EA, Vogel JS, Ognibene TJ, Malfatti MA, Kulp K, Haack KW.

Methods Mol Biol. 2014;1105:147-57. doi: 10.1007/978-1-62703-739-6_12.

PMID:
24623226
21.

Controlling the diameter, monodispersity, and solubility of ApoA1 nanolipoprotein particles using telodendrimer chemistry.

He W, Luo J, Bourguet F, Xing L, Yi SK, Gao T, Blanchette C, Henderson PT, Kuhn E, Malfatti M, Murphy WJ, Cheng RH, Lam KS, Coleman MA.

Protein Sci. 2013 Aug;22(8):1078-86. doi: 10.1002/pro.2292. Epub 2013 Jun 27.

22.

The hue of concepts.

Albertazzi L, Canal L, Malfatti M, Micciolo R.

Perception. 2013;42(12):1344-52.

PMID:
24649636
23.

Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry.

Malfatti MA, Palko HA, Kuhn EA, Turteltaub KW.

Nano Lett. 2012 Nov 14;12(11):5532-8. doi: 10.1021/nl302412f. Epub 2012 Oct 17.

24.

Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo.

Neuwirth C, Mosesso P, Pepe G, Fiore M, Malfatti M, Turteltaub K, Dekant W, Mally A.

Mol Nutr Food Res. 2012 Sep;56(9):1363-74. doi: 10.1002/mnfr.201200226. Epub 2012 Aug 3.

25.

The hue of shapes.

Albertazzi L, Da Pos O, Canal L, Micciolo R, Malfatti M, Vescovi M.

J Exp Psychol Hum Percept Perform. 2013 Feb;39(1):37-47. doi: 10.1037/a0028816. Epub 2012 Jun 18.

PMID:
22708741
26.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX.

Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

27.

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN Jr, Turteltaub K, Henderson P, Pan CX.

Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. doi: 10.1021/tx1003547. Epub 2010 Oct 28.

28.

A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach.

Chen C, Ma X, Malfatti MA, Krausz KW, Kimura S, Felton JS, Idle JR, Gonzalez FJ.

Chem Res Toxicol. 2007 Mar;20(3):531-42. Epub 2007 Feb 6.

29.

Mutagenic potency of food-derived heterocyclic amines.

Felton JS, Knize MG, Wu RW, Colvin ME, Hatch FT, Malfatti MA.

Mutat Res. 2007 Mar 1;616(1-2):90-4. Epub 2006 Dec 11. Review.

PMID:
17161439
30.

The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans.

Malfatti MA, Dingley KH, Nowell-Kadlubar S, Ubick EA, Mulakken N, Nelson D, Lang NP, Felton JS, Turteltaub KW.

Cancer Res. 2006 Nov 1;66(21):10541-7.

31.

Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

Ma X, Idle JR, Malfatti MA, Krausz KW, Nebert DW, Chen CS, Felton JS, Waxman DJ, Gonzalez FJ.

Carcinogenesis. 2007 Mar;28(3):732-7. Epub 2006 Oct 19.

32.

What do diet-induced changes in phase I and II enzymes tell us about prevention from exposure to heterocyclic amines?

Felton JS, Malfatti MA.

J Nutr. 2006 Oct;136(10):2683S-4S. No abstract available.

PMID:
16988149
33.
35.
36.

Impact of environmental exposures on the mutagenicity/carcinogenicity of heterocyclic amines.

Felton JS, Knize MG, Bennett LM, Malfatti MA, Colvin ME, Kulp KS.

Toxicology. 2004 May 20;198(1-3):135-45. Review.

PMID:
15138037
37.

Human exposure to heterocyclic amine food mutagens/carcinogens: relevance to breast cancer.

Felton JS, Knize MG, Salmon CP, Malfatti MA, Kulp KS.

Environ Mol Mutagen. 2002;39(2-3):112-8. Review.

PMID:
11921178
39.

Liquid chromatography-tandem mass spectrometry method of urine analysis for determining human variation in carcinogen metabolism.

Knize MG, Kulp KS, Malfatti MA, Salmon CP, Felton JS.

J Chromatogr A. 2001 Apr 20;914(1-2):95-103.

PMID:
11358237
40.
41.

Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses.

Turteltaub KW, Dingley KH, Curtis KD, Malfatti MA, Turesky RJ, Garner RC, Felton JS, Lang NP.

Cancer Lett. 1999 Sep 1;143(2):149-55.

PMID:
10503895
42.

In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

Lang NP, Nowell S, Malfatti MA, Kulp KS, Knize MG, Davis C, Massengill J, Williams S, MacLeod S, Dingley KH, Felton JS, Turteltaub KW.

Cancer Lett. 1999 Sep 1;143(2):135-8.

PMID:
10503892
43.

The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans.

Malfatti MA, Kulp KS, Knize MG, Davis C, Massengill JP, Williams S, Nowell S, MacLeod S, Dingley KH, Turteltaub KW, Lang NP, Felton JS.

Carcinogenesis. 1999 Apr;20(4):705-13.

PMID:
10223203
44.

Health risks of heterocyclic amines.

Felton JS, Malfatti MA, Knize MG, Salmon CP, Hopmans EC, Wu RW.

Mutat Res. 1997 May 12;376(1-2):37-41. Review.

PMID:
9202736
45.
46.
47.
48.
49.

[Use of the shading technic for the study of "Mycobacterium leprae"].

MALFATTI M.

Sem Med. 1959 Dec 10;115:948-57. Spanish. No abstract available.

PMID:
14420288
50.

[Contribution of electron microscopy to the L forms in microbiology & human pathology].

MALFATTI MG, NOTA NR.

Prensa Med Argent. 1957 Oct 25;44(43):3182-9. Spanish. No abstract available.

PMID:
13542463

Supplemental Content

Loading ...
Support Center